⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26917162 | 1.00 | — | — | |
| SCHEMBL28281798 | 1.00 | — | — | |
| SCHEMBL30212181 | 0.86 | — | — | |
| SCHEMBL28266841 | 0.78 | APLNR (0.43) | — | |
| SCHEMBL241029 | 0.75 | — | — | |
| SCHEMBL3082231 | 0.75 | — | — | |
| SCHEMBL3629190 | 0.74 | — | — | |
| SCHEMBL5037136 | 0.74 | — | — | |
| SCHEMBL28629043 | 0.74 | KDM4E (0.46) | — | |
| SCHEMBL16492788 | 0.74 | KDM4E (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528820-A | Apricoxiyet Synthesis method of tam | 浙江国邦药业有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119528820-B | Apricoxiyet Synthesis method of tam | 浙江国邦药业有限公司 | 2025-10-10 | — | — | CN | disclosed |
| CN-119528820-A | Apricoxiyet Synthesis method of tam | 浙江国邦药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119528820-A | Apricoxiyet Synthesis method of tam | 浙江国邦药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024249642-A1 | EGFR INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4347590-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117715909-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| EP-2733141-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | Shionogi & Co., Ltd. (JP) | 2014-05-21 | — | — | EP | disclosed |
| WO-2014002054-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| EP-1144415-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042045-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5726172-A | BENZOXAZINONE DERIVATIVES; TREATMENT OF PRETERM LABOR, DYSMENORRHEA | MERCK & CO., INC. (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1997025992-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0475214-B1 | Caffeic acid derivatives and pharmaceutical compositions containing the same | SUNTORY LTD (JP) | 1995-06-07 | — | — | EP | disclosed |
| US-5326785-A | Arteriosclerosis andn diseases of the circulatory system | SUNTORY LIMITED (JP) | 1994-07-05 | — | — | US | disclosed |
| US-5232941-A | Therapeutic agents for diseases of the circulatory system | SUNTORY LIMITED (JP) | 1993-08-03 | — | — | US | disclosed |
| EP-0475214-A1 | Caffeic acid derivatives and pharmaceutical compositions containing the same | SUNTORY LIMITED (JP) | 1992-03-18 | — | — | EP | disclosed |